AUPH - Aurinia Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
+0.01 (+0.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close20.36
Bid20.33 x 800
Ask20.38 x 800
Day's Range19.92 - 20.45
52 Week Range3.52 - 21.93
Avg. Volume3,612,175
Market Cap2.231B
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.92
  • Business Wire

    Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2019 at 10:00 a.m. ET in New York, NY.

  • 3 “Strong Buy” Small-Cap Stocks with Towering Growth Prospects

    3 “Strong Buy” Small-Cap Stocks with Towering Growth Prospects

    Finding a stock which will deliver enormous returns is the Street’s holy grail. Upon first glance, this task may seem rather simple. Step 1 is to pinpoint a company with a small market cap and low valuation, preferably one that remains a relatively well-kept secret. Step 2: invest in said undiscovered gem, and then sit back and watch in gleeful awe as the initial investment multiplies itself repeatedly.While these thoughts are fanciful, they are not entirely unrealistic. Just ask anyone who invested in Netflix a decade ago, or in Amazon a decade before. It is possible to find other small-cap names poised to hand over similar returns these giants provided early investors, although admittedly, they are relatively rare and hard to come by. After all, if this was so easily achievable, we would all be filthy rich.With this in mind, we went on our own intrepid search for small-cap stocks, specifically ones which the Street thinks have enormous growth potential. Using TipRanks’ Stock Screener, we were able to get the scoop on three promising tickers. It appears that apart from the upside potential, all three also currently boast a “Strong Buy” consensus rating from Wall Street analysts. Here are the details.Aurinia Pharmaceuticals (AUPH)As biotechs tend to do, Aurinia’s share price soared majestically in early December. The surge followed the news that positive efficacy and safety results were achieved in a Phase 3 trial using voclosporin, the company’s candidate for the treatment of lupus nephritis. By the end of the month, Aurinia stock was trading 141% higher than it was before the news broke. If the orphan disease-focused biopharma continues in the same vein, it won’t be long before it outstrips its $2.1 billion market cap.Lupus (System Lupus Erythematosus – SLE) is a chronic condition which affects more than half a million people in the US, the majority of which are women. The disease can affect the heart, lungs and kidneys, amongst other parts of the body. Lupus nephritis (LN) is an inflammation of the kidney that represents a serious progression of SLE.Aurinia is expected to file an NDA for voclosporin’s use in treating patients with LN sometime in the first half of 2020, with potential approval by 2021. The drug is currently in trials for other indications, with results from a Phase 2/3 study using ophthalmic voclosporin to treat dry eye syndrome expected in 2H20.For Jefferies’ Maury Raycroft, the results were reason enough to take a bullish stance on Aurinia. The 4-star analyst said, "AUPH recently reported positive Phase 3 data that showed lead asset voclosporin (VCS) was effective and safe in lupus nephritis (LN) -- removal of the safety overhang was critical. Given clear need for approved LN agents and VCS' differentiated profile, we believe AUPH has an appealing opportunity ahead. After the LN Phase 3, we also believe VCS potential in FSGS and dry eye syndrome (DES) is more de-risked."Raycroft, therefore, initiated coverage on Aurinia with a Buy rating and set a price target of $27. The figure conveys the analyst’s belief that Aurinia has potential upside of 44% left in the tank. (To watch Raycroft’s track record, click here)The biopharma gets total support from the Street as of now; 5 Buys add up to a unanimous Strong Buy consensus rating. At $25, the average price target suggests 32% will be added to Aurinia’s share price over the next 12 months. (See Aurinia stock analysis on TipRanks) TTEC Holdings (TTEC)Hovering around roughly the same market cap as Aurinia, we come across TTEC Holdings. The $1.9 billion company, though, is an entirely different beast.TTEC deals in customer experience technology and services, with its digital offerings including AI enabled cloud platforms and CX (customer experience) consulting solutions. 2019 was a good one for TTEC, as its share price grew by 41% along the way. According to some fans on the Street, 2020 is shaping up to be much of the same.The company has several partnerships with household names in place. On January 22, TTEC announced a new contract with Volkswagen Group UK to oversee its digital transformation and provide customer experience solutions. The contract comes hot on the heels of new strategic alliances with LivePerson and Cisco Contact Center. Additionally, in October, TTEC acquired FCR, a customer experience provider for a multitude of industries that include high tech, e-commerce and gaming, amongst others.Northland’s Michael Latimore is a believer in the TTEC story. According to the 4-star analyst, the company’s expanded cloud contact center and AI partnerships are set to increase its growth opportunities. Latimore also notes that TTEC provides the highest-rated agent services to global 1,000 companies. This prompted the analyst to initiate coverage on the global tech services provider. The newly bestowed Outperform rating comes alongside a price target of $60. Bottom line? Latimore expects an 46% to be added to TTEC’s share price over the next year. (To watch Latimore’s track record, click here)Merrill Lynch’s Jason Kupferberg is another analyst siding with the bulls. The 5-star analyst believes TTEC’s competitive positioning, key partnerships and market leading position in customer experience technology and services are good enough reasons to initiate coverage with a Buy rating and $48 price target. (To watch Kupferberg’s track record, click here)And what about the rest of the Street? All good news, it appears. 4 Buy ratings coalesce into a Strong Buy consensus rating. The average price target comes in at $55, and implies further room for upside in the shape of 34%. (See TTEC stock analysis on TipRanks) Skyline Champion Corporation (SKY)SKY is in fact a relatively new company, created in June 2018 following a merger between Skyline and Champion Enterprises. Now, the company is one of the largest publicly traded factory-built-housing names in the US. With a market cap of $1.6 billion, it is the smallest company on our list. Don’t be fooled, though, by the relatively small figure, as this builder of manufactured and modular homes had a stellar 2019.The rally, though, came to an end last week with the release of the company’s latest earnings report, following which, the share price has dropped by over 20%. Despite the fact that EPS of $0.30 beat the estimate, revenue came in below expectations, down by 3.5% year-over-year to $342.2 million.So, following the earnings disappointment, should you stay away from the home builder? On the contrary, thinks SunTrust Robinson’s Rohit Seth. The 4-star analyst highlights Skyline’s M&A flexibility, superior positioning to cyclical and secular tailwinds, as well as its continued self-help opportunities as reasons for the company’s "significant estimate upside potential."As a result, the 4-star analyst kept his Buy rating on Sky and liked the company’s builder developer strategy enough to bump up his price target. The new target was raised from $40 to $45, and implies upside potential of 56% over the coming months. (To watch Seth’s track record, click here)Skyline’s Strong Buy consensus rating breaks down into 3 Buys and 1 Hold. Analysts, on average, expect the share price to reach $38.25 over the next 12 months, a figure which could provide gains of 32%. (See Skyline stock analysis on TipRanks)

  • Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock

    Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock

    Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

  • Do Directors Own Aurinia Pharmaceuticals Inc. (TSE:AUP) Shares?
    Simply Wall St.

    Do Directors Own Aurinia Pharmaceuticals Inc. (TSE:AUP) Shares?

    Just because a business does not make any money, does not mean that the stock will go down. By way of example, Aurinia...


    My Top Stock Pick for 2020 Is a Super Strong Finisher From 2019

    There will be other stocks that do better, but this one has the potential of a big gain but with limited downside.

  • Hedge Funds Have Never Been More Bullish On Aurinia Pharmaceuticals Inc (AUPH)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Aurinia Pharmaceuticals Inc (AUPH)

    Is Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds […]

  • Why Biotech ETFs are Surging to New Highs

    Why Biotech ETFs are Surging to New Highs

    increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

  • Benzinga

    The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

    Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...

  • Benzinga

    The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...


    A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know

    Another biotech company, (ACAD) (ACAD), also saw its stock jump 14%. There is sure to be more big biotech news coming up. It makes sense for GM to pair up with LG Chem (051910.Korea), rather than go it alone.


    Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data

    Drug-trial news sent shares of Aurinia Pharmaceuticals soaring Thursday morning and Sage Pharmaceuticals tumbling.

  • Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up

    Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up

    Aurinia's (AUPH) lupus candidate, voclosporin, met primary endpoint of renal response rate in a late-stage study. An NDA is expected in the first half of 2020.

  • Benzinga

    The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...

  • MarketWatch

    Aurinia Pharmaceuticals surges more than 110%, after positive trial for lupus-related drug

    Aurinia Pharmaceuticals Inc. stock rampaged in the extended session, rising more than 110% after the company announced positive efficacy and safety results from a Phase 3 trial for a drug that treats a common complication of lupus, an autoimmune disease. The complication known as lupus nephritis is a frequent complication of the disease commonly known as lupus. "This extraordinary pivotal data confirms voclosporin's ability to achieve statistically significant improvements in clinically meaningful endpoints for this complex disease, with a comparable safety profile to the current standard of care," Chief Medical Officer Neil Solomons said in a statement. "This data represents a significant advance for people living with LN, which can lead to irreversible kidney damage, eventual kidney failure and death." The company's drug is called voclosporin, and Aurinia said it expects that if it achieves regulatory approval then patent protection for the drug will be extended in the U.S. and Europe, among other markets, until 2027. Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia and trades on the Toronto Stock Exchange and the Nasdaq. Prior to Wednesday's after-hours stock move, Aurinia stock had gained 23% this year, as the S&P 500 index also rose 23%.

  • Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8%

    Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8%

    Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

  • Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit
    Simply Wall St.

    Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit

    Aurinia Pharmaceuticals Inc.'s (TSE:AUP): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company...

  • Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

    Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

    Aurinia (AUPH) delivered earnings and revenue surprises of -10.53% and 360.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Were Hedge Funds Right About Souring On Aurinia Pharmaceuticals Inc (AUPH)?
    Insider Monkey

    Were Hedge Funds Right About Souring On Aurinia Pharmaceuticals Inc (AUPH)?

    The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]